Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).

Abstract: The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is 2?6?-Dmt-D-Arg-Phe-Lys-NH2 or Phe-D-Arg-Phe-Lys-NH2.

Abstract: Incorporation of an exogenous large-vocabulary model into rule-based speech recognition is provided. An audio stream is received by a local small-vocabulary rule-based speech recognition system (SVSRS), and is streamed to a large-vocabulary statistically-modeled speech recognition system (LVSRS). The SVSRS and LVSRS perform recognitions of the audio. If a portion of the audio is not recognized by the SVSRS, a rule is triggered that inserts a mark-up in the recognition result. The recognition result is sent to the LVSRS. If a mark-up is detected, recognition of a specified portion of the audio is performed. The LVSRS result is unified with the SVSRS result and sent as a hybrid response back to the SVSRS. If the hybrid-recognition rule is not triggered, an arbitration algorithm is evoked to determine whether the SVSRS or the LVSRS recognition has a lesser word error rate. The determined recognition is sent as a response to the SVSRS.

Abstract: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.

Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.

Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

Abstract: The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.

Abstract: The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.

Abstract: The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2?,6?-Dmt-Lys-Phe-NH2.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of peptide modulators of PKC isozymes (“PMPKCs”), and/or naturally or artificially occurring derivatives, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to PMPKCs and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.

Abstract: A voice command definition file (VCDF) declaratively defines voice commands for an application. For example, the VCDF may include definitions for: voice commands; one or more phrases/utterances that may be said to execute each of the commands; a navigation location to navigate to within the application (e.g. a page); phrase lists containing items that may be used as a parameter in a voice command; examples; feedback; and the like. A user may say a single utterance to launch the application, navigate to the associated location of the command and execute the command. The VCDF may define multiple ways to listen for a particular command. The VCDF may be edited/defined by a user and may include a user friendly name for an application. A speech engine loads the VCDF for use such that it may recognize the commands associated with an application. The definitions may be updated during runtime.

Abstract: The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.

Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of at least one iron chelator, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to at least one iron chelator and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.

Abstract: The disclosure generally describes methods of preventing or treating Lebers hereditary optic neuropathy (LHON). The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: Disclosed herein are compositions and methods related to aromatic-cationic peptides. In particular, the compositions and methods relate to aromatic-cationic peptides in conjunction with cytochrome c.

Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.

Abstract: A voice command definition file (VCDF) declaratively defines voice commands for an application. For example, the VCDF may include definitions for: voice commands; one or more phrases/utterances that may be said to execute each of the commands; a navigation location to navigate to within the application (e.g. a page); phrase lists containing items that may be used as a parameter in a voice command; examples; feedback; and the like. A user may say a single utterance to launch the application, navigate to the associated location of the command and execute the command. The VCDF may define multiple ways to listen for a particular command. The VCDF may be edited/defined by a user and may include a user friendly name for an application. A speech engine loads the VCDF for use such that it may recognize the commands associated with an application. The definitions may be updated during runtime.